Drug discovery for psychiatric disorders
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Royal Society of Chemistry
2012
|
| Schriftenreihe: | RSC drug discovery series
no. 28 |
| Schlagworte: | |
| Online-Zugang: | DE-1046 DE-1047 Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV043102868 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2012 xx o|||| 00||| eng d | ||
| 020 | |a 1849733651 |9 1-84973-365-1 | ||
| 020 | |a 1849734941 |c electronic bk. |9 1-84973-494-1 | ||
| 020 | |a 9781849733656 |9 978-1-84973-365-6 | ||
| 020 | |a 9781849734943 |c electronic bk. |9 978-1-84973-494-3 | ||
| 035 | |a (OCoLC)819343535 | ||
| 035 | |a (DE-599)BVBBV043102868 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 615.78 |2 23 | |
| 245 | 1 | 0 | |a Drug discovery for psychiatric disorders |c edited by Zoran Rankovic ... [et al.] |
| 264 | 1 | |a Cambridge |b Royal Society of Chemistry |c 2012 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a RSC drug discovery series |v no. 28 | |
| 500 | |a The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism | ||
| 650 | 7 | |a MEDICAL / Pain Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Psychiatry / Psychopharmacology |2 bisacsh | |
| 650 | 4 | |a Psychotropic Drugs | |
| 650 | 4 | |a Psychopharmacology | |
| 650 | 7 | |a Psychopharmacology |2 fast | |
| 650 | 7 | |a Psychotropic drugs |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Psychotropic drugs | |
| 650 | 4 | |a Psychopharmacology | |
| 700 | 1 | |a Ranković, Zoran |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-028527059 | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376 |l DE-1046 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376 |l DE-1047 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1819295416231919616 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043102868 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)819343535 (DE-599)BVBBV043102868 |
| dewey-full | 615.78 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.78 |
| dewey-search | 615.78 |
| dewey-sort | 3615.78 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03563nam a2200481zcb4500</leader><controlfield tag="001">BV043102868</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2012 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849733651</subfield><subfield code="9">1-84973-365-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849734941</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-84973-494-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849733656</subfield><subfield code="9">978-1-84973-365-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849734943</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-84973-494-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)819343535</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043102868</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.78</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug discovery for psychiatric disorders</subfield><subfield code="c">edited by Zoran Rankovic ... [et al.]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Royal Society of Chemistry</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">RSC drug discovery series</subfield><subfield code="v">no. 28</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pain Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Psychiatry / Psychopharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic Drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Psychopharmacology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Psychotropic drugs</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ranković, Zoran</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028527059</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376</subfield><subfield code="l">DE-1046</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376</subfield><subfield code="l">DE-1047</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043102868 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-24T04:41:51Z |
| institution | BVB |
| isbn | 1849733651 1849734941 9781849733656 9781849734943 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028527059 |
| oclc_num | 819343535 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Royal Society of Chemistry |
| record_format | marc |
| series2 | RSC drug discovery series |
| spelling | Drug discovery for psychiatric disorders edited by Zoran Rankovic ... [et al.] Cambridge Royal Society of Chemistry 2012 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier RSC drug discovery series no. 28 The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism MEDICAL / Pain Medicine bisacsh MEDICAL / Psychiatry / Psychopharmacology bisacsh Psychotropic Drugs Psychopharmacology Psychopharmacology fast Psychotropic drugs fast Medizin Psychotropic drugs Ranković, Zoran Sonstige oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376 Aggregator Volltext |
| spellingShingle | Drug discovery for psychiatric disorders MEDICAL / Pain Medicine bisacsh MEDICAL / Psychiatry / Psychopharmacology bisacsh Psychotropic Drugs Psychopharmacology Psychopharmacology fast Psychotropic drugs fast Medizin Psychotropic drugs |
| title | Drug discovery for psychiatric disorders |
| title_auth | Drug discovery for psychiatric disorders |
| title_exact_search | Drug discovery for psychiatric disorders |
| title_full | Drug discovery for psychiatric disorders edited by Zoran Rankovic ... [et al.] |
| title_fullStr | Drug discovery for psychiatric disorders edited by Zoran Rankovic ... [et al.] |
| title_full_unstemmed | Drug discovery for psychiatric disorders edited by Zoran Rankovic ... [et al.] |
| title_short | Drug discovery for psychiatric disorders |
| title_sort | drug discovery for psychiatric disorders |
| topic | MEDICAL / Pain Medicine bisacsh MEDICAL / Psychiatry / Psychopharmacology bisacsh Psychotropic Drugs Psychopharmacology Psychopharmacology fast Psychotropic drugs fast Medizin Psychotropic drugs |
| topic_facet | MEDICAL / Pain Medicine MEDICAL / Psychiatry / Psychopharmacology Psychotropic Drugs Psychopharmacology Psychotropic drugs Medizin |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519376 |
| work_keys_str_mv | AT rankoviczoran drugdiscoveryforpsychiatricdisorders |